Terms: = Lung cancer AND RAD21, HR21, 5885, ENSG00000164754, KIAA0078, FLJ25655, hHR21, MCD1, O60216, NXP1, HRAD21, FLJ40596, SCC1 AND Treatment
10 results:
1. Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma.
Kinnaman MD; Zaccaria S; Makohon-Moore A; Arnold B; Levine MF; Gundem G; Arango Ossa JE; Glodzik D; Rodríguez-Sánchez MI; Bouvier N; Li S; Stockfisch E; Dunigan M; Cobbs C; Bhanot UK; You D; Mullen K; Melchor JP; Ortiz MV; O'Donohue TJ; Slotkin EK; Wexler LH; Dela Cruz FS; Hameed MR; Glade Bender JL; Tap WD; Meyers PA; Papaemmanuil E; Kung AL; Iacobuzio-Donahue CA
Cancer Res; 2023 Nov; 83(22):3796-3812. PubMed ID: 37812025
[TBL] [Abstract] [Full Text] [Related]
2. Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell lung cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB.
Chen J; Wei S; Zhao T; Zhang X; Wang Y; Zhang X
Dis Markers; 2022; 2022():7137357. PubMed ID: 35945957
[TBL] [Abstract] [Full Text] [Related]
3. Clinical outcomes of image-guided proton therapy for histologically confirmed stage I non-small cell lung cancer.
Nakajima K; Iwata H; Ogino H; Hattori Y; Hashimoto S; Toshito T; Hayashi K; Akita K; Baba F; Nakamae K; Mizoe JE; Shibamoto Y
Radiat Oncol; 2018 Oct; 13(1):199. PubMed ID: 30305125
[TBL] [Abstract] [Full Text] [Related]
4. Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.
Iida M; Bahrar H; Brand TM; Pearson HE; Coan JP; Orbuch RA; Flanigan BG; Swick AD; Prabakaran PJ; Lantto J; Horak ID; Kragh M; Salgia R; Kimple RJ; Wheeler DL
Mol Cancer Ther; 2016 Sep; 15(9):2175-86. PubMed ID: 27422810
[TBL] [Abstract] [Full Text] [Related]
5. The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer.
Zhao J; Fu W; Liao H; Dai L; Jiang Z; Pan Y; Huang H; Mo Y; Li S; Yang G; Yin J
BMC Cancer; 2015 Oct; 15():731. PubMed ID: 26482648
[TBL] [Abstract] [Full Text] [Related]
6. Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial.
Jamal-Hanjani M; A'Hern R; Birkbak NJ; Gorman P; Grönroos E; Ngang S; Nicola P; Rahman L; Thanopoulou E; Kelly G; Ellis P; Barrett-Lee P; Johnston SR; Bliss J; Roylance R; Swanton C
Ann Oncol; 2015 Jul; 26(7):1340-6. PubMed ID: 26003169
[TBL] [Abstract] [Full Text] [Related]
7. Enhancement of radiation response with bevacizumab.
Hoang T; Huang S; Armstrong E; Eickhoff JC; Harari PM
J Exp Clin Cancer Res; 2012 Apr; 31(1):37. PubMed ID: 22538017
[TBL] [Abstract] [Full Text] [Related]
8. Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancer.
Nowsheen S; Bonner JA; Lobuglio AF; Trummell H; Whitley AC; Dobelbower MC; Yang ES
PLoS One; 2011; 6(8):e24148. PubMed ID: 21912620
[TBL] [Abstract] [Full Text] [Related]
9. Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets.
Røe OD; Anderssen E; Sandeck H; Christensen T; Larsson E; Lundgren S
Lung Cancer; 2010 Jan; 67(1):57-68. PubMed ID: 19380173
[TBL] [Abstract] [Full Text] [Related]
10. Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer.
Kruser TJ; Armstrong EA; Ghia AJ; Huang S; Wheeler DL; Radinsky R; Freeman DJ; Harari PM
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):534-42. PubMed ID: 18793955
[TBL] [Abstract] [Full Text] [Related]
